Summary of Study ST000560
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000411. The data can be accessed directly via it's Project DOI: 10.21228/M8XG7R This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST000560 |
Study Title | Metabolomics of immunoglobulin-producing cells in IgA nephropathy |
Study Summary | IgA nephropathy (IgAN), the most common primary glomerulonephritis, is characterized by deposits of IgA-containing immune complexes in the kidney glomeruli, as first described by Berger and Hinglais in 1968. IgAN is a major cause of end-stage renal disease with its associated cardio-renal morbidity and mortality. Analyses of the IgA deposits revealed that the IgA is exclusively of the IgA1 subclass and that this IgA1 is aberrantly glycosylated, deficient in galactose in some O-glycans (Gd-IgA1). Patients with IgAN have elevated serum levels of Gd-IgA1 bound by anti-glycan autoantibodies in circulating immune complexes (CIC) that are fundamental in driving disease pathology in an autoimmune process. We have recently shown that elevated serum levels of Gd-IgA1 in patients with IgAN predict disease progression. Thus, understanding the mechanisms behind Gd-IgA1 production will improve future treatment options, as there is presently no disease-specific therapy. A total of 24 cell pellets (4 replicates from 6 cell lines) were analyzed by LCMS metabolomics. Immortalized immunoglobulin-producing cell lines were generated from peripheral-blood lymphocytes from patients with IgAN and healthy controls as described in Suzuki, H., Moldoveanu, Z., Hall, S., et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008, 118, 629-639. |
Institute | RTI International |
Laboratory | NIH Eastern Regional Comphrehensive Metabolomics Resource Core at UNC Chapel Hill (ERCMRC) |
Last Name | Sumner |
First Name | Susan |
Address | 3040 E. Cornwallis Road, Research Triangle Park, NC 27709 |
susan_sumner@unc.edu | |
Phone | 704-250-5000 |
Submit Date | 2017-02-17 |
Num Groups | 2 |
Total Subjects | 24 |
Raw Data Available | Yes |
Raw Data File Type(s) | raw(Waters) |
Analysis Type Detail | LC-MS |
Release Date | 2018-04-10 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR000411 |
Project DOI: | doi: 10.21228/M8XG7R |
Project Title: | Metabolomics of immunoglobulin-producing cells in IgA nephropathy |
Project Summary: | IgA nephropathy (IgAN), the most common primary glomerulonephritis, is characterized by deposits of IgA-containing immune complexes in the kidney glomeruli, as first described by Berger and Hinglais in 1968. IgAN is a major cause of end-stage renal disease with its associated cardio-renal morbidity and mortality. Analyses of the IgA deposits revealed that the IgA is exclusively of the IgA1 subclass and that this IgA1 is aberrantly glycosylated, deficient in galactose in some O-glycans (Gd-IgA1). Patients with IgAN have elevated serum levels of Gd-IgA1 bound by anti-glycan autoantibodies in circulating immune complexes (CIC) that are fundamental in driving disease pathology in an autoimmune process. We have recently shown that elevated serum levels of Gd-IgA1 in patients with IgAN predict disease progression. Thus, understanding the mechanisms behind Gd-IgA1 production will improve future treatment options, as there is presently no disease-specific therapy. A total of 24 cell pellets (4 replicates from 6 cell lines) were analyzed by LCMS metabolomics. Immortalized immunoglobulin-producing cell lines were generated from peripheral-blood lymphocytes from patients with IgAN and healthy controls as described in Suzuki, H., Moldoveanu, Z., Hall, S., et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008, 118, 629-639. |
Institute: | University of Alabama, Birmingham |
Department: | Departments of Microbiology and Medicine |
Last Name: | Novak |
First Name: | Jan |
Address: | 845 19th St.South, BBRB 761A |
Email: | jannovak@uab.edu |
Phone: | 205-934-4480 |
Funding Source: | NIH/NIGMS Grant # K01GM109320 to Jessica Gooding; NIDDK Grant # K01DK106341 to Colin Reily; NIDDK Grant # DK078244 to Jan Novak and NIH Common Fund ERCMRC Grant # U24DK097193 to Susan Sumner |
Contributors: | Jessica Gooding1,2, Colin Reily3, Courtney Whitaker1,2, Hieu Sy Vu1,2, Zach Acuff1,2, Susan McRitchie1,2, Bruce A. Julian3, Jan Novak3, Susan Sumner2,4 1Analytical Chemistry & Pharmaceutics, RTI International, RTP, NC 2NIH Eastern Regional Comprehensive Metabolomics Resource Core (ERCMRC) at UNC Chapel Hill, NC 3Departments of Microbiology and Medicine, University of Alabama at Birmingham, Birmingham, AL 4Nutrition Research Institute, University of North Carolina, Chapel Hill, NC |
Subject:
Subject ID: | SU000582 |
Subject Type: | Cells |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Cell Strain Details: | Suzuki, H., Moldoveanu, Z., Hall, S., et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Inv. 2008, 118, 629-639 |
Cell Primary Immortalized: | immortalized |
Cell Counts: | 1x10^7 cells / pellet |
Species Group: | Mammals |
Factors:
Subject type: Cells; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Phenotype |
---|---|---|
SA028898 | HC3_2 | HC |
SA028899 | HC3_3 | HC |
SA028900 | HC3_4 | HC |
SA028901 | HC2_4 | HC |
SA028902 | HC1_1 | HC |
SA028903 | HC3_1 | HC |
SA028904 | HC2_3 | HC |
SA028905 | HC1_2 | HC |
SA028906 | HC1_4 | HC |
SA028907 | HC1_3 | HC |
SA028908 | HC2_1 | HC |
SA028909 | HC2_2 | HC |
SA028910 | IgAN3_2 | IgAN |
SA028911 | IgAN3_1 | IgAN |
SA028912 | IgAN2_4 | IgAN |
SA028913 | IgAN3_4 | IgAN |
SA028914 | IgAN3_3 | IgAN |
SA028915 | IgAN1_3 | IgAN |
SA028916 | IgAN2_3 | IgAN |
SA028917 | IgAN1_1 | IgAN |
SA028918 | IgAN1_2 | IgAN |
SA028919 | IgAN1_4 | IgAN |
SA028920 | IgAN2_2 | IgAN |
SA028921 | IgAN2_1 | IgAN |
SA028922 | Pool_5 | Pool |
SA028923 | Pool_4 | Pool |
SA028924 | Pool_1 | Pool |
SA028925 | Pool_2 | Pool |
SA028926 | Pool_3 | Pool |
Showing results 1 to 29 of 29 |
Collection:
Collection ID: | CO000576 |
Collection Summary: | An aliquot of cells (1 x 10^7) grown in suspension culture was transferred into a 15 mL conical tube containing 4x the culture volume of ice-cold 0.9% (w/v) NaCl. Cells were pelleted for 5 minutes at 1,500 rpm in a 4oC refrigerated centrifuge. Supernatant was removed, and the pellet was gently resuspended in 1 mL of ice-cold 0.9% (w/v) NaCl to wash and transfer into a 2 mL Lo-Bind microcentrifuge tube (Eppendorf, #022431102). Cells were pelleted for 3 minutes at 1,300 rcf in a 4oC refrigerated centrifuge. The entire supernatant was removed and pellets were snap-frozen in liquid nitrogen and immediately stored at -70°C. |
Sample Type: | Cell pellets |
Storage Conditions: | -80 C |
Tissue Cell Quantity Taken: | 1 x 10^7 |
Treatment:
Treatment ID: | TR000596 |
Treatment Summary: | None |
Cell Media: | 10%FBS, 11mM Glucose |
Sample Preparation:
Sampleprep ID: | SP000589 |
Sampleprep Summary: | A total of 24 cell pellets (4 replicates from 6 cell lines) were shipped to the NIH RTI-RCMRC on dry ice and immediately stored at -80oC after being inventoried for metabolomics analysis. An addition of 500 µL of ice-cold Cell Extraction buffer (0.005 tryptophan-d5 in 50:50 Acetonitre:Water) was added to tubes containing the cell pellet samples on ice. MagNA Lyser ceramic beads (~15-20, prewashed & dried) were added to the tubes and the MagNA Lyser was used to beat samples for two 30 sec pulses at 2,000 rpm and samples were placed on a cold block for 1 min between pulses. Samples were then centrifuged at room temperature at 16,000 rcf for 4 min. A 15 mL washed conical tube was labeled Total Pool and 120 µL of each sample was added to this conical tube. There were 24 samples; thus, the resulting Total Pool was 2880 µL. The Total Pool was vortexed and 150 µL of the Total Pool was transferred to pre-labeled 1.5 mL Lo-Bind Eppendorf tubes to make two sets of 5 Total Pool samples, and 3 Equilibrium samples. The 150 uL of the remaining supernatants of each sample was transferred to a new, pre-labeled 1.5 mL Lo-Bind Eppendorf tubes and capped with disposable rubber stoppers. Samples were placed at -80 °C for 1 h and lyophilized overnight. 100 µL of 95:5 Acetonitrile:Water was added to each tube and vortexed for 2 min at 5000 rpm, followed by centrifugation at room temperature at 16,000 rcf for 4 min. The supernatants were transferred to pre-labeled autosampler vials and 3 µL was injected into SYNAPT G2-Si. All samples were prepared and analyzed in a randomized order. |
Combined analysis:
Analysis ID | AN000860 | AN000861 |
---|---|---|
Analysis type | MS | MS |
Chromatography type | HILIC | HILIC |
Chromatography system | Waters Acquity I-Class | Waters Acquity I-Class |
Column | Waters Acquity BEH Amide (150 x 2.1mm,1.7um) | Waters Acquity BEH Amide (150 x 2.1mm,1.7um) |
MS Type | ESI | ESI |
MS instrument type | QTOF | QTOF |
MS instrument name | Waters Synapt-G2-Si | Waters Synapt-G2-Si |
Ion Mode | POSITIVE | NEGATIVE |
Units | normalized ion counts | normalized ion counts |
Chromatography:
Chromatography ID: | CH000612 |
Chromatography Summary: | Hydrophilic Interaction Liquid Chromatography (HILIC) Gradient Seperation |
Instrument Name: | Waters Acquity I-Class |
Column Name: | Waters Acquity BEH Amide (150 x 2.1mm,1.7um) |
Chromatography Type: | HILIC |
MS:
MS ID: | MS000761 |
Analysis ID: | AN000860 |
Instrument Name: | Waters Synapt-G2-Si |
Instrument Type: | QTOF |
MS Type: | ESI |
Ion Mode: | POSITIVE |
MS ID: | MS000762 |
Analysis ID: | AN000861 |
Instrument Name: | Waters Synapt-G2-Si |
Instrument Type: | QTOF |
MS Type: | ESI |
Ion Mode: | NEGATIVE |